Cartesian Therapeutics, Inc. (United States)
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- $300.2M
CAR T-cell Therapy Pipeline Surges with 180+ Companies Advancing Novel Cancer Treatments
The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.
Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 3 Trial
Cartesian Therapeutics secured FDA agreement for Phase 3 trial of Descartes-08 in myasthenia gravis, potentially leading to BLA submission.
Novel Therapies and Vaccines Poised to Reshape Community Pharmacy in 2025
Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.
Cartesian Therapeutics Advances mRNA Cell Therapies for Autoimmune Diseases
Cartesian Therapeutics is set to begin Phase 3 AURORA trial of Descartes-08 for myasthenia gravis in the first half of 2025.
CAR T-Cell Therapy Shows Promise in Treating Autoimmune Diseases: Clinical Trials and Future Directions
UChicago Medicine launched a Phase 2 clinical trial to explore CAR T-cell therapy for systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis.
Cartesian Therapeutics Advances Myasthenia Gravis Treatment with Phase 3 Trial of Descartes-08
Cartesian Therapeutics is set to begin a Phase 3 trial (AURORA) for Descartes-08, an mRNA CAR-T therapy, in patients with acetylcholine receptor autoantibody positive (AChR Ab+) myasthenia gravis (MG).
Cartesian Therapeutics' Descartes-08 Receives FDA Agreement for Phase 3 Myasthenia Gravis Trial
Cartesian Therapeutics received FDA agreement under the Special Protocol Assessment for its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.
FDA Grants Rare Pediatric Disease Designation to Cartesian's Descartes-08 for Juvenile Dermatomyositis
The FDA has granted Rare Pediatric Disease Designation to Cartesian Therapeutics' Descartes-08 for treating juvenile dermatomyositis (JDM).
Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 2b Trial
Cartesian Therapeutics' Descartes-08 met the primary endpoint in a Phase 2b trial for myasthenia gravis, demonstrating statistically significant improvement in MGC scores.
Cartesian Therapeutics Doses First Patient in Phase 1 Trial of mRNA CAR-T Therapy Descartes-15 for Multiple Myeloma
Cartesian Therapeutics initiated a phase 1 clinical trial for Descartes-15, a novel mRNA-engineered CAR-T therapy, in relapsed/refractory multiple myeloma patients.